Novartis AG (NVS) has risen sharply, recording gains of 4.75% in the past 4 weeks. However, the stock has corrected -0.63% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 0.36% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has recorded a 20-day Moving Average of 1.42% and the 50-Day Moving Average is 3.71%.
Novartis AG (NYSE:NVS): The stock opened at $81.77 on Friday but the bulls could not build on the opening and the stock topped out at $82.00 for the day. The stock traded down to $81.46 during the day, due to lack of any buying support eventually closed down at $81.61 with a loss of -0.50% for the day. The stock had closed at $82.02 on the previous day. The total traded volume was 1,292,159 shares.
The company Insiders own 0.01% of Novartis AG shares according to the proxy statements. Institutional Investors own 9.95% of Novartis AG shares.
Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.